Alsatinib (Dasatinib) Tablet

Description

Description

This page contains brief details about the drug dasatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Dasatinib is an anticancer agent which was approved for its medical use on 28th June 2006.

Mechanism of Action of Dasatinib

Dasatinib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a tyrosine kinase inhibitor. The BCR ABL tyrosine kinase enzymes are responsible for the uncontrolled generation of white blood cells in leukemia. Dasatinib binds to both active and inactive sites of BCR ABL tyrosine kinase enzyme to inhibit the uncontrolled growth of white blood cells.

Uses of Dasatinib

Dasatinib Tablet has been developed to treat Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia in adults, adolescents and children who have not benefitted from previous therapies. It is also approved for treating chronic myeloid leukemia.

Dasatinib Dosage available

The recommended starting dose for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia is 140 mg per day. The ideal dose for children is calculated based on their body weight.

Dasatinib is available as a tablet in doses 20mg, 50mg, 70mg, and 100mg. It is advisable to take the tablets at the same time each day. Swallow them whole with some water and do not crush, cut or chew them.